In this review:
MRI activity vs relapses as markers of disease activity in SPMS
If and when to stop DMT in relapsing MS
If and when to stop DMT in progressive MS
Difficulties in diagnosis of PPMS
Economic burden of SPMS
Real-world experience with ocrelizumab in patients with PPMS
Humoral immune response to SARS-CoV-2 vaccines in patients with MS
The impact of smoking cessation on MS disease progression
Vaccinations in patients with MS
Bexarotene causes agedependent remyelination in patients with RRMS
Please login below to download this issue (PDF)